Related Experiment Video
Updated: May 29, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Fast DNA and protein microarray tests for the diagnosis of hepatitis C virus infection on a single platform
Stuart W J Ember1, Holger Schulze, Alan J Ross
1Division of Pathway Medicine, College of Medicine and Veterinary Medicine, The University of Edinburgh, Chancellor's Building, Little France Crescent, Edinburgh EH16 4SB, UK.
Insights
Researchers developed rapid DNA and protein microarrays for Hepatitis C virus (HCV) detection. Assay times were significantly reduced without compromising performance, paving the way for faster point-of-care diagnostics.
Area of Science:
- Infectious Disease Diagnostics
- Biotechnology
- Molecular Biology
Background:
- Hepatitis C virus (HCV) causes chronic liver disease and cancer, posing a significant global health burden.
- Current diagnostic methods can be time-consuming, limiting their use in point-of-care settings.
- Rapid and sensitive detection of HCV is crucial for timely treatment and disease management.
Purpose of the Study:
- To develop and evaluate a rapid microarray-based diagnostic platform for Hepatitis C virus (HCV).
- To assess the feasibility of reducing assay time-to-result (TTR) for point-of-care applications.
- To compare the performance of DNA and protein microarrays for HCV detection.
Main Methods:
- Development of a single-platform DNA microarray for HCV RNA detection and a protein microarray for anti-HCV antibody detection.
- Optimization of hybridization and washing steps to reduce assay duration.
- Validation using artificial targets and clinical samples from an HCV seroconversion panel.
- Evaluation of sensitivity and performance across different HCV genotypes.
Main Results:
- Assay time for anti-HCV antibody detection reduced to 14 minutes with nanomolar sensitivity.
- Protein microarray demonstrated analytical sensitivity comparable to commercial systems.
- DNA microarray achieved a post-PCR assay time of 16 minutes (down from 150 minutes) without sensitivity loss.
- Reduced assay times did not impair overall diagnostic performance.
Conclusions:
- Rapid microarray-based diagnostics for infectious diseases, including HCV, are feasible.
- Significant reductions in assay time are achievable without compromising diagnostic accuracy.
- The protein microarray shows promise as a rapid, sensitive, and potentially point-of-care diagnostic tool for HCV.
Abstract:
Hepatitis C virus (HCV) is a major cause of chronic liver disease and liver cancer, and remains a large health care burden to the world. In this study we developed a DNA microarray test to detect HCV RNA and a protein microarray to detect human anti-HCV antibodies on a single platform. A main focus of this study was to evaluate possibilities to reduce the assay time, as a short time-to-result (TTR) is a prerequisite for a point-of-care test. Significantly reducing hybridisation and washing times did not impair the assay performance. This was confirmed first using artificial targets and subsequently using clinical samples from an HCV seroconversion panel derived from a HCV-infected patient. We were able to reduce the time required for the detection of human anti-HCV antibodies to only 14 min, achieving nanomolar sensitivity. The protein microarray exhibited an analytical sensitivity comparable to that of commercial systems. Similar results were obtained with the DNA microarray using a universal probe which covered all different HCV genotypes. It was possible to reduce the assay time after PCR from 150 min to 16 min without any loss of sensitivity. Taken together, these results constitute a significant step forward in the design of rapid, microarray-based diagnostics for human infectious disease, and show that the protein microarray is currently the most favourable candidate to fill this role.
More Related Videos
Related Concept Videos
02:34DNA Microarrays
01:25Hepatitis
02:07FISH - Fluorescent In-situ Hybridization